AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26814620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26814620 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 40
Study 25135738 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 kV tube voltage imaging (Group A)
Number of subjects: 300
Study 25135738 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV tube voltage imaging (Group B)
Number of subjects: 300
Study 25135738 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV tube voltage imaging (Group C)
Number of subjects: 300
Study 22790464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C antiviral therapy offered to patients in opioid agonist treatment
Number of subjects: 19
Study 20962312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil beverage (1.5 g per day for 12 weeks)
Number of subjects: 10
Study 16761217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical climate training for 8 days
Number of subjects: 16
Study 16761217 — intervention group
Group type: COMPARATOR
Intervention: Altitude training for 8 days
Number of subjects: 16
Study 16761217 — intervention group
Group type: COMPARATOR
Intervention: Tapering group
Number of subjects: 16
Study 16225928 — intervention group
Group type: EXPERIMENTAL
Intervention: Early retreatment with verteporfin therapy every 2 months (group A)
Number of subjects: 203
Study 16225928 — intervention group
Group type: COMPARATOR
Intervention: Standard verteporfin therapy every 3 months (group B)
Number of subjects: 203
Study 16225928 — intervention group
Group type: EXPERIMENTAL
Intervention: Early retreatment with verteporfin therapy (group A)
Number of subjects: 203
Study 16225928 — intervention group
Group type: COMPARATOR
Intervention: Standard verteporfin therapy (group B)
Number of subjects: 203
Study 12047482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalat OROS (fasted state)
Number of subjects: 24
Study 12047482 — intervention group
Group type: EXPERIMENTAL
Intervention: Slofedipine XL (fasted state)
Number of subjects: 24
Study 12047482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalat OROS (fed state)
Number of subjects: 24
Study 12047482 — intervention group
Group type: EXPERIMENTAL
Intervention: Slofedipine XL (fed state)
Number of subjects: 24
Study 9933797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cell cultures (CL) from RCC
Number of subjects: 27
Study 9933797 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture of gamma delta and alpha beta T cell clones with tumor CL
Number of subjects: 27
Study 7555554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment education program (six sessions, one session per week)
Number of subjects: 0
Study 7555554 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (no intervention during the first 6 weeks)
Number of subjects: 0
Study 2246637 — intervention group
Group type: EXPERIMENTAL
Intervention: 3- to 5-minute unstructured physician discussion encouraging smoking cessation (intervention group)
Number of subjects: 463
Study 2246637 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 463
Study 2246637 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (smokers in practices not involved in delivering the intervention)
Number of subjects: 463
Study 2246637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year follow-up (all groups)
Number of subjects: 463
Study 7398005 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 28
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8 weeks
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 8 weeks
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 12 weeks
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 12 weeks
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 12 weeks (Interferon-experienced)
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir with Ribavirin for 12 weeks (Interferon-experienced)
Number of subjects: 255
Study 29666174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir plus Ribavirin (previously treated with sofosbuvir)
Number of subjects: 255
Study 29561188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin-Metformin (SITA-MET)
Number of subjects: 36
Study 27218868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg/d for 1 week and then 30 mg/d for 12 weeks)
Number of subjects: 430
Study 27218868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 27218868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 430
Study 25270432 — intervention group
Group type: EXPERIMENTAL
Intervention: Social activation and physical mobilization program, four times a week for eight weeks
Number of subjects: 85
Study 25270432 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 85
Study 22283926 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced itch
Number of subjects: 16
Study 22283926 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 20059593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular infiltration anaesthesia
Number of subjects: 89
Study 20059593 — intervention group
Group type: COMPARATOR
Intervention: Mandibular block anaesthesia
Number of subjects: 89
Study 17379124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 26
Study 17379124 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 26
Study 15589927 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 200
Study 15589927 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 200
Study 12711119 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil plus Tegafur (UFT) for 2 years (adjuvant group)
Number of subjects: 221
Study 12711119 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone (control group)
Number of subjects: 221
Study 10640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implant
Number of subjects: 61
Study 10640160 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic implant
Number of subjects: 61
Study 10640160 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study 7589771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor (0.6 mg/day) combined with sulphonylurea (glibenclamide or tolbutamide) for 4 weeks
Number of subjects: 10
Study 2287705 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 31
Study 2287705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2287705 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal conditions
Number of subjects: 31
Study 2287705 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol concentration
Number of subjects: 31
Study 2287705 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of dieting (beta-hydroxybutric acid and triiodothyronine)
Number of subjects: 31
Study 2287705 — intervention group
Group type: EXPERIMENTAL
Intervention: Height correlations
Number of subjects: 31
Study 7015536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of penbutolol (40 mg) and furosemide (20 mg)
Number of subjects: 12
Study 7015536 — intervention group
Group type: COMPARATOR
Intervention: Reference formulations: Penbutolol capsules (40 mg) and furosemide (20 mg) tablets
Number of subjects: 12
Study 31342099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular brachial plexus block
Number of subjects: 68
Study 31342099 — intervention group
Group type: COMPARATOR
Intervention: Sedoanalgesia
Number of subjects: 68
Study 30046804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined explicit-implicit (E-I) intervention
Number of subjects: 25
Study 30046804 — intervention group
Group type: COMPARATOR
Intervention: Implicit-only (I-O) intervention
Number of subjects: 25
Study 26220329 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive physical activity combined with therapeutic patient education (APA-TPE)
Number of subjects: 126
Study 26220329 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study 24549525 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Initiative for Lifelong Eating and Exercise (CHILE) intervention
Number of subjects: 1879
Study 22244781 — intervention group
Group type: EXPERIMENTAL
Intervention: hphMG
Number of subjects: 749
Study 22244781 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 749
Study 19282782 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/ddI-based cART
Number of subjects: 650
Study 19282782 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC or d4T/3TC-based cART
Number of subjects: 650
Study 19282782 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based cART
Number of subjects: 650
Study 17187597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre and nasopharyngeal continuous positive airway pressure (CPAP)
Number of subjects: 48
Study 15878470 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss interventions (behavioral, surgical, pharmacologic)
Number of subjects: 34
Study 11929440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy programme for adult survivors of child abuse and neglect
Number of subjects: 83
Study 11929440 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist) group
Number of subjects: 83
Study 9617508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (mean daily dose 8.7 mg in early therapy; 8.2 mg in adjunct therapy)
Number of subjects: 1364
Study 9617508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 1364
Study 9617508 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 1364
Study 8034821 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback with regular home practice (HP)
Number of subjects: 17
Study 8034821 — intervention group
Group type: COMPARATOR
Intervention: Thermal biofeedback without home practice (NHP)
Number of subjects: 17
Study 2656070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2; 1.4 pmol min‐1 kg‐1; 5 ng min‐1 kg‐1)
Number of subjects: 16
Study 2656070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) during ANG II infusion
Number of subjects: 16
Study 2656070 — intervention group
Group type: COMPARATOR
Intervention: ANG II alone
Number of subjects: 16
Study 31794684 — intervention group
Group type: EXPERIMENTAL
Intervention: VDOT
Number of subjects: 405
Study 31794684 — intervention group
Group type: COMPARATOR
Intervention: DOT
Number of subjects: 405
Study 29547447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic treadmill exercise (ATM)
Number of subjects: 19
Study 29547447 — intervention group
Group type: COMPARATOR
Intervention: Land treadmill exercise (LTM)
Number of subjects: 19
Study 27000764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconventional DBS settings (narrow pulse widths, square biphasic pulses, irregular pulse patterns)
Number of subjects: 11
Study 27000764 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow pulse widths
Number of subjects: 11
Study 27000764 — intervention group
Group type: EXPERIMENTAL
Intervention: Square biphasic pulses
Number of subjects: 11
Study 27000764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconventional settings
Number of subjects: 11
Study 27000764 — intervention group
Group type: COMPARATOR
Intervention: Sham and clinically-optimal settings
Number of subjects: 11
Study 24933702 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization during encoding (nameability of the stimuli)
Number of subjects: 0
Study 24933702 — intervention group
Group type: EXPERIMENTAL
Intervention: Postencoding verbalization (verbal descriptions)
Number of subjects: 0
Study 24933702 — intervention group
Group type: EXPERIMENTAL
Intervention: Final memory task demands (global or featural)
Number of subjects: 0
Study 22428773 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 43
Study 22428773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 19966072 — intervention group
Group type: EXPERIMENTAL
Intervention: VA‐MEDIC intervention (n = 58)
Number of subjects: 118
Study 19966072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 18490793 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive competence feedback
Number of subjects: 0
Study 18490793 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16158373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Step (IS)
Number of subjects: 3
Study 16158373 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Step (CS)
Number of subjects: 3
Study 16158373 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3
Study 12865276 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilatation (EBD)
Number of subjects: 202
Study 12865276 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 202
Study 10370187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10370187 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg salbutamol Turbuhaler
Number of subjects: 40
Study 10370187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol Turbuhaler
Number of subjects: 40
Study 10370187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol pMDI
Number of subjects: 40
Study 8848911 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced analgesia (5 ml of 2% lidocaine gel on the clips and 200 mg of ketoprofen i.v.)
Number of subjects: 90
Study 8848911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of placebo gel on the clips and placebo i.v.)
Number of subjects: 90
Study 8848911 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine group (5 ml of 2% lidocaine gel on the clips and placebo i.v.)
Number of subjects: 90
Study 8504578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (bolus doses of 5 + 5 mmol followed by infusion of 0.04 mmol/min)
Number of subjects: 57
Study 8504578 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (5 + 5 mg followed by 0.1 mg/min)
Number of subjects: 57
Study 3306903 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 25
Study 3306903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30325117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen cannula (HFNC)
Number of subjects: 100
Study 30325117 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 100
Study 26381515 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 130
Study 26381515 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 130
Study 26381515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (CP and Erlotinib)
Number of subjects: 130
Study 26381515 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (in mucinous tumour patients)
Number of subjects: 130
Study 23234601 — intervention group
Group type: COMPARATOR
Intervention: pegIFNα‐2a continuing monotherapy (group A, n = 51)
Number of subjects: 85
Study 23234601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (ADV) add‐on therapy (group B, n = 34)
Number of subjects: 85
Study 21670455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1217
Study 21670455 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 1217
Study 19539117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical myofascial induction technique
Number of subjects: 35
Study 19539117 — intervention group
Group type: COMPARATOR
Intervention: Sham-manual procedure
Number of subjects: 35
Study 17085752 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity self-efficacy (PASE) measured with 19 items
Number of subjects: 473
Study 17085752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable self-efficacy (FVSE) measured with 21 items
Number of subjects: 473
Study 17085752 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRT modeling to assess SocD influences
Number of subjects: 473
Study 17085752 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurement of physical activity using CSA/MTI accelerometer
Number of subjects: 473
Study 17085752 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire for total fruit, juice, and vegetable consumption
Number of subjects: 473
Study 15261701 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor agonist bromocriptine 3.125 mg
Number of subjects: 20
Study 15261701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10680473 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO (300 IU/kg on day four before surgery and 150 IU/kg daily for the following seven days)
Number of subjects: 81
Study 10680473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10680473 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO
Number of subjects: 81
Study 8975318 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting 99mTc-MIBI SPECT after nitroglycerine (NTG) administration
Number of subjects: 31
Study 8975318 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting 99mTc-MIBI SPECT delayed images
Number of subjects: 31
Study 8975318 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting delayed and NTG MIBI imaging
Number of subjects: 31
Study 8975318 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (Rev)
Number of subjects: 31
Study 1757606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 104
Study 1757606 — intervention group
Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate ointment
Number of subjects: 104
Study 6552999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenalin
Number of subjects: 140
Study 6552999 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 140
Study 28819778 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumihaidokuto (6 g daily)
Number of subjects: 21
Study 28819778 — intervention group
Group type: COMPARATOR
Intervention: Control (antihistamines only)
Number of subjects: 21
Study 27655039 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided ICBT (velibra) plus care as usual (CAU)
Number of subjects: 139
Study 27655039 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 139
Study 27655039 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided ICBT (velibra)
Number of subjects: 139
Study 25833401 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous PEG‐IFN‐β1a
Number of subjects: 1500
Study 25833401 — intervention group
Group type: COMPARATOR
Intervention: Conventional IFN‐β drugs
Number of subjects: 1500
Study 21987832 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable membranes applied to skin for the first 7 days of life
Number of subjects: 42
Study 21987832 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control Group)
Number of subjects: 42
Study 21366847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCTZ 150/12.5 mg
Number of subjects: 451
Study 21366847 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 451
Study 19570341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 11216
Study 19570341 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11216
Study 17127381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (35 microg/h)
Number of subjects: 0
Study 17127381 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release morphine (60 mg/day)
Number of subjects: 0
Study 15153857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light absorber (UVA) and hindered amine light stabilizer (HALS)
Number of subjects: 160
Study 15153857 — intervention group
Group type: COMPARATOR
Intervention: Control (nonpigmented elastomers)
Number of subjects: 160
Study 15153857 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA and HALS
Number of subjects: 160
Study 11264125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial flap technique
Number of subjects: 36
Study 11264125 — intervention group
Group type: COMPARATOR
Intervention: 20% ethanol debridement
Number of subjects: 36
Study 9385692 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine epidural corticosteroid injections
Number of subjects: 108
Study 9385692 — intervention group
Group type: COMPARATOR
Intervention: Rest and a nonsteroidal antiinflammatory drug
Number of subjects: 108
Study 8016793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 19
Study 8016793 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Expiration Technique (FET)
Number of subjects: 19
Study 8016793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 3142566 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals containing varying ratios of whole cereal grains (barley or cracked wheat) to milled flour (75:25, 50:50, 0:100)
Number of subjects: 16
Study 3142566 — intervention group
Group type: COMPARATOR
Intervention: Standard white bread control meals
Number of subjects: 16
Study 4934047 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorphanol 2 mg
Number of subjects: 13
Study 4934047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 13
Study 4934047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 20 mg
Number of subjects: 13